Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study

European Urology
Eero KaasinenNordic Urothelial Cancer Group

Abstract

To evaluate whether, in patients with carcinoma in situ (CIS) of the urinary bladder, alternating instillation therapy with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) was more effective and less toxic than conventional BCG monotherapy. Patients were stratified prospectively for primary, secondary, and concomitant CIS and randomized to one of two regimens. Patients in the alternating group received six weekly intravesical instillations of MMC 40 mg, followed by alternating monthly instillations of BCG 120 mg and MMC for one year. In the monotherapy group, only BCG was instilled on the same schedule. Of 323 enrolled patients, 304 were eligible for analysis. After an overall median follow-up of 56 months, the Kaplan-Meier disease-free estimate for BCG monotherapy was significantly better than that for alternating therapy (p=0.03; log rank test). Risk for progression appeared lower in the BCG monotherapy group (p=0.07), but no differences existed in survival. Besides the regimen, CIS category also predicted outcome to some extent. BCG monotherapy caused significantly more local side-effects and premature cessation of instillation treatment than did the alternating therapy. However, no differences were observed in the numb...Continue Reading

References

May 16, 1992·BMJ : British Medical Journal·I S Fentiman
Jul 1, 1997·The Journal of Urology·M S CooksonW R Fair
Mar 4, 2000·The Urologic Clinics of North America·G Dalbagni, H W Herr
Jun 21, 2002·European Urology·Willem OosterlinckUNKNOWN European Association of Urology (EAU) Working Group on Oncological Urology
Feb 22, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Francisco J PasquelAdriana G Ioachimescu

❮ Previous
Next ❯

Citations

Nov 30, 2010·World Journal of Urology·Alon Z WeizerJeffrey S Montgomery
Mar 29, 2008·Pharmaceutical Research·Zancong ShenJessie L-S Au
Jul 5, 2005·European Urology·Adrian P M van der MeijdenUNKNOWN EAU Working Party on Non Muscle Invasive Bladder Cancer
Aug 6, 2003·Critical Reviews in Oncology/hematology·Per-Uno Malmström
Dec 22, 2006·Expert Review of Anticancer Therapy·David Y JosephsonJohn P Stein
Jun 29, 2011·Expert Review of Anticancer Therapy·William M HiltonRobert S Svatek
Dec 21, 2010·BJU International·Richard P MeijerRuud Bosch
Jan 10, 2006·Urology·Richard J SylvesterKarl Heinz Kurth
Dec 11, 2014·World Journal of Urology·Tom J H ArendsJ Alfred Witjes
Jul 29, 2011·Scandinavian Journal of Urology and Nephrology·Karsten Zieger, Klaus Møller-Ernst Jensen
Jul 16, 2005·Scandinavian Journal of Urology and Nephrology·Eberhard VarenhorstJan-Erik Johansson
Nov 16, 2013·The Journal of Urology·Tammer HemdanUNKNOWN Members of the Urothelial Cancer Group of the Nordic Association of Urology
Jun 22, 2016·European Urology·Marko BabjukRichard Zigeuner
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maha H A HussainColin P Dinney
Jan 27, 2005·Scandinavian Journal of Urology and Nephrology·Patrik AndiusSten Holmäng
Mar 13, 2014·Nature Reviews. Urology·Homayoun ZargarPeter Black
Aug 23, 2019·Nature Reviews. Urology·Gregory A JoiceMax Kates
Jan 9, 2020·The Cochrane Database of Systematic Reviews·Stefanie SchmidtJoerg J Meerpohl
Nov 26, 2016·Der Urologe. Ausg. A·M E AutenriethK Scheidhauer
Apr 8, 2004·Current Opinion in Oncology·Lester S BordenM Craig Hall
May 6, 2004·The Journal of Urology·Donald L Lamm

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.